Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 5/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | MAP3K14 | Q99558 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27199251 | 0.90 | KDM1A (0.50) | KDM1ASLC6A4SLC6A3HTR2AHTR2C | |
| SCHEMBL3896827 | 0.81 | SIGMAR1 (0.36) | KDM1ASIGMAR1 | |
| SCHEMBL6568570 | 0.81 | KDM1A (0.53) | KDM1ASLC6A4SLC6A3 | |
| SCHEMBL7976327 | 0.79 | KDM1A (0.45) | KDM1ASLC6A4SLC6A3KDM4CSIGMAR1 | |
| SCHEMBL1333907 | 0.78 | KDM1A (0.47) | KDM1ASIGMAR1HTR2AHTR2C | |
| SCHEMBL6567499 | 0.77 | KDM1A (0.48) | KDM1ASIGMAR1 | |
| SCHEMBL11086002 | 0.74 | KDM4C (0.35) | KDM1ASLC6A4SLC6A3KDM4C | |
| SCHEMBL23376916 | 0.73 | MAP3K14 (0.55) | KDM1AHTR2AHTR2CMAP3K14 | |
| SCHEMBL23376859 | 0.73 | MAP3K14 (0.55) | KDM1AHTR2AHTR2CMAP3K14 | |
| SCHEMBL17361959 | 0.73 | APP (0.39) | KDM1AKDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1382333-B1 | Use of beta 3 adrenergic receptor agonists in the treatment of dysuria | ASTELLAS PHARMA INC (JP) | 2009-02-25 | — | — | EP | disclosed |
| US-7217706-B2 | Propanolamine derivatives | ASTELLAS PHARMA INC. (JP) | 2007-05-15 | — | — | US | disclosed |
| US-20040198791-A1 | Fused imidazole derivative | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-10-07 | — | — | US | disclosed |
| EP-1403256-A1 | FUSED IMIDAZOLE DERIVATIVE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-31 | — | — | EP | disclosed |
| EP-1382333-A2 | Use of beta 3 adrenergic receptor agonists in the treatment of dysuria | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-01-21 | — | — | EP | disclosed |
| US-6495546-B1 | SUCH AS 1-(N-BENZYL-N-(3-METHOXY-6,7,8,9-TETRAHYDRO-5H-BENZO-CYCLOHEPTEN-6-YL)AMINO)-3-PHENOXY-2-PROPANOL; ADRENERGIC RECEPTOR AGONISTS; ANTIULCEROUS, LIPOLYTIC, ANTIURINARY INCONTINENCE AND ANTIPOLLAKIURIA ACTIVITIES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-12-17 | — | — | US | disclosed |
| US-20020120148-A1 | Propanolamine derivatives | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2002-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198791-A1 | Fused imidazole derivative | H1-0, H1-5, H1-3 | KDM1A 2636/4885SLC6A4 2991/4885SLC6A3 3131/4885 |
| US-20020120148-A1 | Propanolamine derivatives | AMY2A, PNMT, PNLIP | KDM1A 1212/4885SLC6A4 801/4885SLC6A3 483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.